The medication prospect glepaglutide is a long-acting GLP-2 analog for the therapy of brief digestive tract disorder.
发布者：BY MARIA OUTZE NIELSEN，转转请注明出处：https://robotalks.cn/zealand-pharma-seeks-ema-approval-of-short-bowel-syndrome-drug/
Zealand Pharma seeks EMA approval of short bowel syndrome drug
赞 (0)
关于作者
Weight-loss medication disguised as cat food: Novo Nordisk thunders against Chinese copy drug suppliers
上一篇
2 6 月, 2025 9:18 上午
EHang “Applying for VT-35 eVTOL Certification”
下一篇
2 6 月, 2025 9:26 上午
相关推荐
-
Sunlight and sugarcane waste power hydrogen production at rate four times higher than commercialization benchmark
An innovation for hydrogen (H2) manufacturing has actually been created by a group of scientists led by Professors Seungho Cho and Kwanyong Search Engine Optimization from the Inst…
-
Texas ranch introduces world’s first homozygous polled Akaushi bull
For the very first time ever before, surveyed Akaushi genes will certainly be openly offered to interested livestock dog breeders– noting a substantial turning point in the t…
-
With potential implications for mechanical systems, study reveals physics of the ‘nick shot’ in squash
In squash, the “nick shot” is an emphatic, point-ending play in which a gamer strikes a sphere that backfires near all-time low of the wall surface and rolls level alon…
-
Five Ways Cobots Enable Manufacturers to Unlock More Value
Browsing today’s production landscape has actually never ever been even more difficult. Organizations are experiencing substantial labor scarcities as infant boomers age righ…
-
Latest dark energy survey data suggest possible variations in dark energy over time
A brand new examine utilizing the Darkish Vitality Survey (DES) remaining datasets suggests potential inconsistencies in the usual cosmological mannequin, often known as ΛCDM. If c…
